2022 Abstract Posters

Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Evaluating Liver Function Status Trends in Hepatocellular Carcinoma Patients with Intermediate Stage Disease Undergoing Radioembolization:
A Longitudinal Study

Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child Pugh A and B cirrhosis: a real world study.

Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Hepatocellular carcinoma tumor burden in the GAN diet-induced obese mouse model of NASH with advanced fibrosis

Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma

Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

PROGNOSTIC ROLE OF ABSOLOUTE LYMPHOCYTE COUNT (ALC) AND NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
TREATED WITH COMBINED IMMUNE CHECKPOINT INHIBITION AND TRANSARTERIAL CHEMOEMBOLIZATION (TACE)